Radiation plus immunotherapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic stomach (gastric) or gastroesophageal junction cancer that is not HER2-positive and is MSS or pMMR.
- You have not received any prior treatment for your cancer, such as chemotherapy, radiation, or immunotherapy.
- You have at least one measurable tumor (visible on scans) and are in generally good health (able to do daily activities, with adequate organ function).
- You are willing to provide tumor and blood samples for research and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (a treatment that helps your immune system fight cancer) with radiation therapy for a certain type of stomach or gastroesophageal junction cancer that has a special genetic marker. The goal is to see if this combination is safe and effective.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This Phase 2 trial tests whether giving a short course of radiation before surgery, along with chemotherapy and a PD-1 immunotherapy drug, can improve treatment outcomes for locally advanced stomach cancer. It may help shrink the tumor before surgery and strengthen the immune system’s attack on cancer.
This trial tests a new sequence of treatments for advanced stomach cancer that has spread to the lining of the abdomen. You would first get low-dose radiation, then a combination of immunotherapy, chemotherapy, and a special type of chemotherapy delivered directly into the belly, to see if it can control the cancer and improve quality of life.
Hear when a new Immune Checkpoint Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.